Alkem Laboratories Limited has informed the Exchange about Intimation for incorporation of Wholly Owned Subsidiary of the Company as a Scientific Office
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories has incorporated a 100% wholly owned subsidiary named 'Alkem Pharmaceuticals Scientific Office FZ LLC' in Dubai Healthcare City, UAE, with effect from 4th February 2026. The subsidiary will focus on manufacturing products and obtaining product registrations in the UAE (trading activities excluded). The entity has an authorized and subscribed share capital of AED 3,670,000 (approximately ₹8-9 crore) divided into 3,670 equity shares of AED 1,000 each, funded entirely through cash. The disclosure also notes that related approvals from the UAE Ministry of Health and Prevention are delayed, reportedly due to ongoing regional conflict.
This is a strategic overseas expansion move to strengthen Alkem's manufacturing footprint and product registration pipeline in the UAE and broader Middle East region. While the capital outlay is modest, delays in UAE health ministry approvals could slow near-term revenue contribution from this subsidiary; investors should watch for updates on regulatory progress.